HC Wainwright Reaffirms Buy Rating for Delcath Systems (NASDAQ:DCTH)

Delcath Systems (NASDAQ:DCTH)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $22.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 72.01% from the stock’s current price.

DCTH has been the topic of several other research reports. Stephens reissued a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.50.

Delcath Systems Stock Up 11.4 %

Shares of NASDAQ:DCTH opened at $12.79 on Tuesday. The business’s 50 day moving average is $11.29 and its 200 day moving average is $9.80. Delcath Systems has a 12-month low of $3.70 and a 12-month high of $13.30. The stock has a market cap of $408.95 million, a price-to-earnings ratio of -9.47 and a beta of 0.87.

Institutional Investors Weigh In On Delcath Systems

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DCTH. Principal Financial Group Inc. purchased a new stake in shares of Delcath Systems during the third quarter worth $808,000. Renaissance Technologies LLC bought a new position in shares of Delcath Systems in the second quarter valued at approximately $694,000. Geode Capital Management LLC grew its stake in Delcath Systems by 3.0% during the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock valued at $2,275,000 after acquiring an additional 7,298 shares in the last quarter. Polar Asset Management Partners Inc. bought a new stake in Delcath Systems during the 3rd quarter worth approximately $1,594,000. Finally, Barclays PLC purchased a new stake in Delcath Systems in the 3rd quarter worth approximately $104,000. 61.12% of the stock is currently owned by institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.